[TS-1 and irradiation combination therapy for head and neck cancer].
5-FU increased the effect of irradiation therapy for cancer. TS-1 is an induced type of 5-FU, so it is also thought to enhance the effect of irradiation therapy for cancer patients. We conducted initial irradiation and TS-1 therapy for stage II to IV for 21 patients. 18 patients were clear this therapy. TS-1 was given at 80 to 100 mg/body/day for 4 weeks. The results were stage II CR 100%, stage III CR 100%, stage IV CR 14% and PR 86%. It was thought that irradiation with TS-1 combination therapy was effective and taking TS-1 was better than injecting patients with anticancer drug for quality of life (QOL).
Kawasaki
Masaru
M
Dept. of Oto-Rino-Laringology, Nagaoka Red Cross Hospital.
Watanabe
Kazumichi
K
Watanabe
Jun
J
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage*; D011788:Quality of Life; D011879:Radiotherapy Dosage; D012074:Remission Induction; D005641:Tegafur / Q000008:administration & dosage*
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid